PMID- 35754684
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2022
DP  - 2022
TI  - The Effect of Curcumin on Lipid Profile and Glycemic Status of Patients with Type 
      2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
PG  - 8278744
LID - 10.1155/2022/8278744 [doi]
LID - 8278744
AB  - Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder, some natural 
      compounds are thought to be beneficial in improving the metabolic status of 
      patients with T2DM. Curcumin is the main bioactive agent of turmeric, the impact 
      of curcumin on T2DM is still controversial. This meta-analysis aimed to evaluate 
      the effects of curcumin on lipids profile and glucose status in patients with 
      T2DM. Randomized controlled trials (RCTs) examining the effects of curcumin on 
      lipids profile and glycemic control of T2DM patients were searched in PubMed, 
      Embase, Web of Science and Cochrane Library. Pooled estimates of weighted mean 
      difference (WMD) were calculated between intervention and control groups using 
      random-effects or fixed-effects model. Subgroup and sensitivity analyses were 
      conducted to assess the effects. Nine eligible RCT with 604 subjects were 
      included. The estimated pooled mean changes with curcumin were -18.97 mg/dL (95% 
      CI: -36.47 to -1.47; P=0.03) for triglyceride (TG), -8.91 mg/dL (95% CI: -14.18 
      to -3.63, P=0.001) for total cholesterol (TC), -4.01 mg/dL (95% CI: -10.96 to 
      2.95, P=0.259) for low density lipoprotein cholesterol (LDL-c), 0.32 mg/dL (95% 
      CI: -0.74 to 1.37, P=0.557) for high density lipoprotein cholesterol (HDL-c), 
      -8.85 mg/dL (95% CI: -14.4 to -3.29, P=0.002) for fasting blood glucose (FBG), 
      -0.54 (95% CI: -0.81 to -0.27, P </= 0.001) for glycated hemoglobin (HbA1c) (%) 
      compared with controls. There was a significant heterogeneity for the influence 
      of curcumin on TG, LDL-c, FBG and HbA1c. Subgroup analysis revealed that the 
      heterogeneity mainly attributed to trial period, curcumin dosage and other 
      therapy. The results of this study showed that curcumin supplementation had 
      beneficial effects on glycemic status and some lipid parameters in patients with 
      T2DM. Further studies with large-scale are still needed to confirm the results.
CI  - Copyright (c) 2022 Jiao Tian et al.
FAU - Tian, Jiao
AU  - Tian J
AUID- ORCID: 0000-0002-3691-7481
AD  - Department of Infection, Ministry of Education Key Laboratory of Child 
      Development and Disorders, National Clinical Research Center for Child Health and 
      Disorders, China International Science and Technology Cooperation Base of Child 
      Development and Critical Disorders, Chongqing Key Laboratory of Child Health and 
      Nutrition, Children's Hospital of Chongqing Medical University, Chongqing 400014, 
      China.
FAU - Feng, Bin
AU  - Feng B
AUID- ORCID: 0000-0002-8379-9983
AD  - State Key Laboratory of Military Stomatology, National Clinical Research Center 
      for Oral Diseases, Shaanxi International Joint Research Center for Oral Diseases, 
      Department of Pharmacy, School of Stomatology, Fourth Military Medical 
      University, Xi'an 710032, China.
FAU - Tian, Zhen
AU  - Tian Z
AUID- ORCID: 0000-0001-9734-7278
AD  - College of Pharmaceutical Sciences, Southwest University, Chongqing 400716, 
      China.
AD  - Department of Pharmacy, Tangdu Hospital, Fourth Military Medical University, 
      Xi'an 710038, China.
LA  - eng
PT  - Journal Article
DEP - 20220617
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC9232354
COIS- The authors declare that there are no conflicts of interest.
EDAT- 2022/06/28 06:00
MHDA- 2022/06/28 06:01
PMCR- 2022/06/17
CRDT- 2022/06/27 03:37
PHST- 2022/04/01 00:00 [received]
PHST- 2022/05/10 00:00 [revised]
PHST- 2022/05/29 00:00 [accepted]
PHST- 2022/06/27 03:37 [entrez]
PHST- 2022/06/28 06:00 [pubmed]
PHST- 2022/06/28 06:01 [medline]
PHST- 2022/06/17 00:00 [pmc-release]
AID - 10.1155/2022/8278744 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2022 Jun 17;2022:8278744. doi: 
      10.1155/2022/8278744. eCollection 2022.